A comparison of specificity and biological activity of polyclonal and monoclonal antibodies raised against Salmonella minnesota R595 lipopolysaccharide
Correspondence should be sent to: Dr N. D. Mehta, Department of Hematology/Oncology, University of Chicago Medical Center, 5841 S. Maryland Avenue, Box 420, Chicago, IL 60637, USA.
Murine monoclonal antibodies (MAbs) and immune rabbit serum were raised against the rough mutant of Salmonella minnesota strain R595. These antibodies were tested for their ability to inhibit LPS-induced B-cell mitogenicity and neutralise LPS toxicity in chick embryos. Immune rabbit serum inhibited both mitogenicity and LPS lethality. None of the MAbs or a cocktail of antibodies were able to neutralise LPS lethality in chick embryos. However, they were able to inhibit mitogenicity by varying degrees.
AppelmelkB J,
Verweij-Van-VughtA M J J,
MaclarenD M,
ThiysL G.
1985; An enzyme-linked immunosorbent assay (ELISA) for the measurement of antibodies to different parts of the gram-negative lipopolysaccharide core region. Journal of Immunological Methods 82:199–207
AppelmelkB J.
1988; Production and characterisation of mouse monoclonal antibodies reacting with the lipopolysaccharide core region of gram-negative bacilli. Journal of Medical Microbiology 26:107–114
BraudeA I,
ZieglerE J,
DouglasH,
McCutchanJ A.
1977; Antibody to cell wall glycolipid of gram-negative bacteria: induction of immunity to bacteremia and endotoxemia. Journal of Infectious Diseases 136:S167–S173
CrowleyJ P,
ZinnerS H,
PeterG.
1982; Opsonization of serumsensitive and serum-resistant Escherichia coli by rough mutant (Re) antisera. Journal of Laboratory and Clinical Medicine 99:197–205
DunnD L,
BogardW C,
CerraF B.
1985; Enhanced survival during murine gram-negative bacterial sepsis by use of a murine monoclonal antibody. Archives of Surgery 120:50–53
DunnD L,
EwaldD C,
ChandanN,
CerraF B.
1986; Immunotherapy of gram-negative bacterial sepsis. A single murine monoclonal antibody provides cross-genera protection. Archives of Surgery 121:58–62
EisensteinT K.
1975; Evidence of O-antigens as the antigenic determinants in “ribosomal” vaccines prepared from Salmonella. Infection and Immunity 12:364–377
GalanosC,
LuderitzO,
WestphalO.
1971; Preparation and properties of antisera against the lipid-A component of bacterial lipopolysaccharides. European Journal Biochemistry 24:116–122
GalanosC,
FreudenbergM,
HaseS,
JayF,
RuschmannE.
1977; Biological activitiesimmunological properties of lipid. SchlessingerD A.
Microbiology American Society of Microbiology Washington, DC:269–276
GreismanS E,
DubuyJ B,
WoodwardC L.
1978; Experimental gram-negative bacterial sepsis : re-evaluation of the ability of rough mutant antisera to protect mice. Proceedings of the Society for Experimental Biology and Medicine 158:482–490
JohnsM,
SkehillA,
McCabeW R.
1983; Immunization with rough mutants of Salmonella minnesota. IV. Protection by antisera to 0 and rough antigens against endotoxin. Journal of Infectious Diseases 147:57–67
KregerB E,
CravenD E,
CarlingP C,
McCabeW R.
1980; Gram-negative bacteremia. 111. Reassessment of etiology, epidemiology and ecology in 61 2 patients. American Journal of Medicine 68:332–343
McCabeW R.
1972; Immunization with R mutants of S minnesota. I. Protection against challenge with heterologous gram-negative bacilli. Journalof Immunology 108:601–610
MehtaN D,
WilsonB M,
RapsonN T,
EasmonC S F.
1988; Comparison of the opsonic activity of polyclonal and monoclonal antibodies raised against Salmonella minnesota R595. Journal of Medical Microbiology 25:85–93
MilnerK C,
FinkelsteinR A.
1966; Bioassay of endotoxin: correlation between pyrogenicity for rabbits and lethality for chick embryos. Journal of Infectious Diseases 116:529–536
NgA K,
ChenC L H,
ChangC M,
NowotnyA.
1976; Relationship of structure to function in bacterial endotoxins : serologically cross-reactive components and their effect on protection of mice against some gram-negative infections. Journalof General Microbiology 94:107–116
PenningtonJ E,
MenkesE.
1981; Type-specific vs. crossprotective vaccination for gram-negative bacterial pneumonia. Journal of Infectious Diseases 144:599–603
PollackM,
RaubitschekA A,
LarrickJ W.
1987; Human monoclonal antibodies that recognize conserved epitopes in the core-lipid A region of lipopolysaccharides. Journal of Clinical Investigation 79:1421–1430
RaubitschekA A,
PollackM,
LarrickJ W.
1985; Preparation of human monoclonal antibodies (mAbs) that react with the conserved core region of endotoxin (LPS). Clinical Research 33:416A
RietschelE T,
SidorczykL,
ZahringerU,
WollenweberH-W,
LuderitzO.
1983; Analysis of the primary structure of lipid A. AndersonL,
UngerF M.
Bacterial lipopolysaccharides. Structure, synthesis, biological activities American Chemical Symposium Series 231 American Chemical Society; Washington, DC:195–218
TaylorR L,
ConradH E.
1972; Stoichiometric depolymerization of polyuronides and glucosaminoglycuronans to monosaccharides following reduction to their carbodiimide-activated carboxyl groups. Biochemistry 11:1383–1388
TelzakE E,
WolffS M.
1985; Immunotherapy and immunoprophylaxis of gram-negative rod bacteremia. RootR K,
SandeM A.
Septic shock Churchill Livingstone; New York:257–276
TengN N H et al.1985; Protection against gram-negative bacteremia and endotoxemia with human monoclonal IgM antibodies. Proceedings of the National Academy of Sciences of the USA 82:1790–1794
Van DijkW C,
VerbrughH A,
Van Erne-Van Der To1M E,
PetersR,
VerhoefJ.
1981; Escherichia coli antibodies in opsonisation and protection against infection. Journal of Medical Microbiology 14:381–389
WestphalO,
JannK.
1965; Bacterial lipopolysaccharides. Extraction with phenol water and further applications of the procedure. Methods in carbohydrate chemistry 5:83–91
ZieglerE J,
DouglasH,
ShermanJ E,
DavisC E,
BraudeA I.
1973; Treatment of E. coli and Klebsiella bacteremia in agranulocytic animals with antiserum to a UDP-Gal epimerase-deficient mutant. Journal of Immunology 111:433–438
ZieglerE J et al.1982; Treatment of gram-negative bacteraemia and shock with human antiserum to a mutant Escherichia coli. New England Journal of Medicine 307:1225–1230
ZinnerS H,
PeterG.
1983; The potential role of cell wall core glycolipids in the immunoprophylaxis and therapy of gramnegative rod bacteraemia. EasmonC S F,
JeljaszewiczJ.
Medical microbiology 11: Academic Press; London:71–851267–1268
A comparison of specificity and biological activity of polyclonal and monoclonal antibodies raised against Salmonella minnesota R595 lipopolysaccharide